Bioelectric Oncology
Reprogramming tumour behaviour through ion channel science
Celex Oncology is developing a new class of cancer therapeutics targeting voltage-gated sodium channels (VGSCs) to reduce invasion, metastasis, and treatment resistance.
Scroll
Science
Targeting the bioelectric drivers of cancer progression
Celex Oncology focuses on voltage-gated sodium channels as upstream regulators of tumour invasion, metastatic potential, and treatment resistance. By modulating aberrant sodium influx, the platform is designed to alter tumour behaviour rather than simply attack proliferating cells.
10
Patent Families
3
Core Programmes
2
Lead Clinical Tracks
1
Platform Focus
02